Bioorthogonally activatable methylene blue platform for selective prodrug activation and fluorescent imaging in living systems
Analytica Chimica Acta · 2026
DOI: 10.1016/j.aca.2025.344988 ↗Kurz gefasst
Fachartikel in der Zeitschrift Analytica Chimica Acta, 2026. Verfasst von Linlin Yang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Xinxiang Key Laboratory of Forensic Science Evidence, School of Forensic Medicine, Henan Medical University, Xinxiang, 453003, Henan Province, PR Chi…. Hauptthemen laut MEDLINE: Prodrugs, Methylene Blue, Optical Imaging, Fluorescent Dyes. Die Arbeit nennt 38 Literaturangaben. Gefördert von: Hainan Association for Science and Technology, Henan Key Laboratory of Biological Psychiatry, Xinxiang Medical University.
Abstract (Originalsprache)
BACKGROUND: The development of fluorescent prodrugs based on bioorthogonal chemistry involves broadening the range of fluorophores that exhibit changes in fluorescence signals and the spatiotemporally regulated release of therapeutic agents upon biorthogonal ligation. However, there are still certain gaps including shallow tissue-penetrating and low drug release efficiency, which limit its application. RESULTS: Herein, we present a flexible and effective bioorthogonal scaffold that allows targeted medication release with simultaneous fluorescence emission when the targeting groups or prodrugs are conjugated. The scaffold consists of a tetrazine-caged methylene blue (MB-Tz), which serves as a dual switch for the activation of fluorophore and drug. Further encountering the TCO-caged molecular partner (TCO-RGD or TCO-Dox) triggers the NIR fluorescence reinstatement and simultaneously leads to spatiotemporal targeting and selective activation of prodrugs inside cancer cells. It was also demonstrated that bioorthogonal activation successfully inhibited tumor growth by controlled activation in vivo, with minimal systemic toxicity observed. SIGNIFICANCE: We envision that integration of fluorescence and bioorthogonal reactions will serve as a general small-molecule-based strategy for precisely targeted imaging and treatment in chemotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Xinxiang Key Laboratory of Forensic Science Evidence, School of Forensic Medicine, Henan Medical University, Xinxiang, 453003, Henan Province, PR China.
- School of Materials Science and Engineering, Henan Normal University, Xinxiang, 453003, Henan Province, PR China. Electronic address: lili0394@yeah.net.
- Xinxiang Key Laboratory of Forensic Science Evidence, School of Forensic Medicine, Henan Medical University, Xinxiang, 453003, Henan Province, PR China; Henan Collaborative Innovation Center of Prevention and Treatment…
Förderung
- Hainan Association for Science and Technology
- Henan Key Laboratory of Biological Psychiatry
- Xinxiang Medical University
- Key Scientific Research Project of Colleges and Universities in Henan Province
Zitieren
APA
Yang, L., Bai, S., Nie, Y., Li, Y., Xin, F., Song, P., Gao, N., Ji, L., Li, L., & He, G. (2026). Bioorthogonally activatable methylene blue platform for selective prodrug activation and fluorescent imaging in living systems. Analytica Chimica Acta. https://doi.org/10.1016/j.aca.2025.344988
Vancouver
Yang L, Bai S, Nie Y, Li Y, Xin F, Song P, et al. Bioorthogonally activatable methylene blue platform for selective prodrug activation and fluorescent imaging in living systems. Analytica Chimica Acta. 2026. doi:10.1016/j.aca.2025.344988
BibTeX
@article{Yang2026,
author = {Yang, Linlin and Bai, Shiqiong and Nie, Yuqing and Li, Yixuan and Xin, Fei and Song, Panpan and Gao, Na and Ji, Liguo and Li, Lili and He, Guangjie},
title = {Bioorthogonally activatable methylene blue platform for selective prodrug activation and fluorescent imaging in living systems},
journal = {Analytica Chimica Acta},
year = {2026},
doi = {10.1016/j.aca.2025.344988}
}
EUVIMED